Assertio Therapeutics (ASRT) AI Stock Analysis

• Market Cap: $69.79M
• Dividend Yield: N/A
• Average Volume (3M): 295.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: -11.42%
• EPS Growth: 89.01%
• Country: US
• Employees: 58
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.11
• Shares Outstanding: 96,239,624
• 10 Day Avg. Volume: 250,113
• 30 Day Avg. Volume: 295,133
• PEG Ratio: 0.04
• Price to Book (P/B): 0.69
• Price to Sales (P/S): 0.66
• P/FCF Ratio: 3.14
• Enterprise Value/Market Cap: 0.13
• Enterprise Value/Revenue: 0.07
• Enterprise Value/Gross Profit: 0.10
• Enterprise Value/Ebitda: 10.17
• 1Y Price Target: $3.00
• Price Target Upside: 275.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $1.00 ▲(25.00% Upside)

Assertio Therapeutics' overall score is driven by its financial challenges, including negative profitability and cash flow concerns. However, the earnings call provided a positive outlook with strong sales growth in key products, which partially offsets the financial weaknesses. Technical indicators suggest a neutral market position, and valuation metrics highlight the company's current financial struggles.

Positive Factors

Rolvedon Sales Growth

The significant increase in Rolvedon sales demonstrates Assertio's ability to expand its market share and enhance revenue streams, supporting long-term growth.

Leadership Change

The appointment of a new CEO with a strong track record in specialty pharmaceuticals is expected to drive strategic growth and operational efficiency.

Cash Flow Improvement

The significant improvement in cash flow indicates enhanced financial health, providing more resources for investment and strategic initiatives.

Negative Factors

Declining Revenue

Declining revenues highlight challenges in maintaining market competitiveness and could impact long-term financial stability.

Indocin Sales Decline

The decline in Indocin sales due to generic competition poses a risk to Assertio's revenue base and market position in pain management.

Profitability Challenges

Ongoing profitability issues indicate structural challenges in cost management and pricing power, affecting long-term financial health.

Assertio Therapeutics Business Overview & Revenue Model

Company Description

Assertio Therapeutics, Inc. (ASRT) is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for patients with pain and other neurological disorders. The company operates primarily in the pharmaceutical sector, with a product portfolio that includes prescription medications designed to address unmet medical needs in pain management and neurological conditions. Assertio aims to enhance patient outcomes through its proprietary formulations and targeted therapies.

How the Company Makes Money

Assertio Therapeutics generates revenue primarily through the sale of its pharmaceutical products. The company markets its approved medications through various channels, including wholesalers, pharmacies, and healthcare providers. Key revenue streams include sales from its flagship products as well as royalties and licensing fees from collaborations with other pharmaceutical companies. Additionally, Assertio may engage in partnerships or collaborations that provide upfront payments and milestone payments tied to the achievement of specific development or commercial objectives, further contributing to its earnings.

Assertio Therapeutics Financial Statement Overview

Summary

Assertio Therapeutics is facing financial challenges with declining revenues and profitability issues. Despite improvements in cash flow generation, negative net income and return on equity highlight the need for strategic changes. The balance sheet is stable, but overall financial health requires attention for long-term viability.

Income Statement

Assertio Therapeutics has experienced declining revenue over recent periods, with a negative revenue growth rate of -1.6% in the TTM. The company also faces significant profitability challenges, as evidenced by negative net profit margins and EBIT margins. Despite a relatively strong gross profit margin of 67.87% in the TTM, the overall income statement reflects financial instability and a need for strategic improvements.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.42 in the TTM, indicating manageable leverage. However, the return on equity is negative, reflecting ongoing losses and a need to improve profitability. The equity ratio is not explicitly calculated, but the company's equity position appears stable relative to its assets.

Cash Flow

Cash flow analysis reveals a significant improvement in free cash flow growth, with a remarkable increase of 183.97% in the TTM. The operating cash flow to net income ratio is positive, suggesting that the company is generating cash despite net losses. However, the sustainability of this cash flow improvement remains uncertain given the negative net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	137.35M	124.96M	152.07M	156.23M	111.01M	106.28M
Gross Profit	93.62M	85.73M	125.05M	137.49M	95.18M	86.40M
EBITDA	899.00K	-24.48M	-222.45M	72.53M	38.78M	-3.20M
Net Income	-28.43M	-21.58M	-331.94M	109.63M	-1.28M	-28.14M
Balance Sheet
Total Assets	319.77M	284.73M	286.42M	413.91M	326.55M	303.27M
Cash, Cash Equivalents and Short-Term Investments	93.43M	100.05M	73.44M	64.94M	36.81M	20.79M
Total Debt	39.17M	40.27M	40.91M	67.27M	75.87M	89.60M
Total Liabilities	213.97M	163.65M	148.42M	188.19M	224.13M	247.76M
Stockholders Equity	105.80M	121.08M	138.00M	225.72M	102.41M	55.51M
Cash Flow
Free Cash Flow	13.33M	26.41M	48.98M	78.32M	5.47M	-65.58M
Operating Cash Flow	13.33M	26.41M	49.60M	78.60M	5.52M	-65.57M
Investing Cash Flow	-12.57M	-48.91M	3.10M	-42.67M	-18.52M	512.80M
Financing Cash Flow	-246.00K	-350.00K	-44.20M	-7.79M	29.03M	-468.55M

Assertio Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.80
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASRT, the sentiment is Positive. The current price of 0.8 is above the 20-day moving average (MA) of 0.79, below the 50-day MA of 0.84, and above the 200-day MA of 0.74, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 50.00 is Neutral, neither overbought nor oversold. The STOCH value of 58.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ASRT.

Assertio Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CPIX	51 Neutral	$39.79M	-12.47	-13.08%	―	12.21%	69.91%
ASRT	50 Neutral	$69.79M	-1.60	-38.40%	―	-11.42%	89.01%
RMTI	47 Neutral	$33.93M	―	-8.65%	―	-6.79%	61.56%
TLPH	41 Neutral	$59.66M	-3.21	-117.56%	―	-93.22%	36.97%
SCYX	41 Neutral	$26.45M	-1.11	-53.29%	―	-65.77%	38.61%
COSM	41 Neutral	$20.93M	-0.68	-52.69%	―	―	―

Assertio Therapeutics Corporate Events

Assertio Therapeutics Reports Strong Q3 2025 Results

Assertio Therapeutics is a pharmaceutical company that specializes in offering differentiated products in the oncology, neurology, and pain management sectors, aiming to address patients’ needs through comprehensive commercial capabilities. In its third-quarter 2025 earnings report, Assertio Therapeutics highlighted significant financial achievements and strategic advancements, including the consolidation of operations under Assertio Specialty Pharmaceuticals and the promotion of Paul Schwichtenberg to President and COO. The company reported a notable increase in Rolvedon net product sales, which rose to $38.6 million, a significant jump from the previous year’s $15.0 million, driven by both normal demand and strategic purchases by national distributors. Sympazan sales also saw an increase, while Indocin sales experienced a decline due to generic competition. The company’s gross margin slightly decreased to 72%, and SG&A expenses saw a marginal increase. Assertio’s adjusted EBITDA rose to $20.9 million, a substantial improvement from the previous year’s $4.4 million. Looking ahead, Assertio’s management remains optimistic about achieving its full-year 2025 guidance, with net product sales expected to range between $110 to $112 million and adjusted EBITDA between $14 to $16 million, reflecting the impact of strategic sales and integration efforts.

Assertio Therapeutics Promotes Paul Schwichtenberg to President

On November 10, 2025, Assertio Holdings, Inc. announced its financial results for the third quarter of 2025, highlighting a significant increase in Rolvedon net product sales, which rose to $38.6 million from $15.0 million in the prior-year quarter. This growth was attributed to both normal demand and large purchases by national distributors. The company also promoted Paul Schwichtenberg to the role of President and Chief Operating Officer, effective November 3, 2025, as part of its strategic efforts to consolidate operations and enhance commercial strategies. Assertio narrowed its full-year 2025 net product sales guidance range to $110 to $112 million and adjusted EBITDA range to $14 to $16 million, reflecting the impact of the Rolvedon pull-forward.

The most recent analyst rating on (ASRT) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Assertio Therapeutics stock, see the ASRT Stock Forecast page.

Assertio Therapeutics Announces New CEO Appointment

On October 27, 2025, Assertio Holdings announced the departure of CEO Brendan O’Grady and the appointment of Mark Reisenauer as the new CEO. This leadership transition aims to accelerate growth and enhance efficiency as the company enters 2026, with Reisenauer bringing extensive experience in oncology and specialty spaces to drive long-term value for shareholders and patients.

The most recent analyst rating on (ASRT) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Assertio Therapeutics stock, see the ASRT Stock Forecast page.

Assertio Therapeutics Amends ROLVEDON Supply Agreement

On October 7, 2025, Spectrum Pharmaceuticals, a subsidiary of Assertio Holdings, and Hanmi Pharmaceutical amended their supply agreement for ROLVEDON drug substance, establishing long-term pricing with a mid-single digit percentage reduction. The amendment allows for price adjustments based on market volume and cost increases, requiring Spectrum’s consent for manufacturing changes, and mandates an annual forecasted purchase plan without minimum purchase requirements.

The most recent analyst rating on (ASRT) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Assertio Therapeutics stock, see the ASRT Stock Forecast page.

Assertio Therapeutics’ Earnings Call: Mixed Sentiments and Strategic Shifts

Assertio Therapeutics’ recent earnings call presented a mixed sentiment, highlighting both positive developments and challenges. The company reported strong demand for its product Rolvedon and successful legal settlements, which are positive indicators. However, it also faced a decline in net product sales and decided to discontinue the commercialization of Otrexup. Despite these challenges, Assertio’s financial position remains robust, supporting future strategic transactions.

Assertio Therapeutics Reports Q2 2025 Financial Results

Assertio Therapeutics is a pharmaceutical company specializing in the commercialization of products in oncology, neurology, and pain management, with a focus on addressing patient needs through differentiated offerings.